Ariad Pharma Says On Track To Complete Strategic Review In Q2 - Quick Facts

(RTTNews) - While reporting its first-quarter financial results today, Ariad Pharmaceuticals Inc. (ARIA) said it is on track to complete its strategic review in the second quarter, aimed at delivering patient and shareholder value.

Paris Panayiotopoulos, president and chief executive officer of ARIAD. "Following our major announcement yesterday with Incyte regarding our agreement to divest our European operations and license the commercial rights to Iclusig in Europe, we are on track to complete our strategic review this quarter aimed at delivering patient and shareholder value."

Panayiotopoulos added, "We also look forward to the presentation of pivotal, registration data on brigatinib at ASCO, along with our planned filing for marketing approval of brigatinib in the U.S. in the third quarter of this year."